NEW YORK, NY, April 21, 2025 (GLOBE NEWSWIRE) -- Meerkat ($MERK), a community-driven meme token project enhanced by AI and ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda. Merck (NYSE: MRK), known as MSD outside of the United States ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

SEC Filings provided by EDGAR Online, Inc.